News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ARTES Biotechnology Issued New Patent in Australia for VLP Technology



4/22/2013 10:38:33 AM

Langenfeld, April 19th, 2013. ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry is pleased to announce the issuance of a new patent for their VLP platform. The patent will further strengthen the Metavax® platform of the company. In combination with the expression platform Hansenula Metavax® is a unique tool for the development of affordable, safe and effective vaccines. “Our intellectual property strategy is to provide multiple layers of protection for our technology platform portfolio. We believe that this new patent will have additional reinforcement to our existing patent estate and for our service we offer clients for vaccine development,” said Dr. Melanie Piontek, Business Development Director of ARTES.

ARTES Biotechnology GmbH – www.artes-biotechnology.com

ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products.

Contact:

ARTES Biotechnology GmbH

Dr. Melanie Piontek

Business Development Director

+49 (0)2173 275870

piontek@artes-biotechnology.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES